David Weill - Feb 27, 2023 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Role
Director
Signature
By: /s/ Stephen Gordon, Attorney-in-Fact
Stock symbol
TMDX
Transactions as of
Feb 27, 2023
Transactions value $
-$370,837
Form type
4
Date filed
2/28/2023, 04:01 PM
Previous filing
Nov 14, 2022
Next filing
May 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMDX Common Stock Options Exercise $84.3K +5.93K +59.34% $14.20* 15.9K Feb 27, 2023 Direct
transaction TMDX Common Stock Sale -$74.8K -964 -6.05% $77.64 15K Feb 27, 2023 Direct F1
transaction TMDX Common Stock Sale -$380K -4.97K -33.2% $76.51 10K Feb 27, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -5.93K -37.24% $0.00 10K Feb 27, 2023 Common Stock 5.93K $14.20 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $77.63 to $77.76, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $76.44 to $76.65, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 A Form 4 filed by the reporting person on November 14, 2022 inadvertently overstated the total number of shares held by the reporting person by 3,500 shares. The updated amounts reported here correct that error and reflect the reporting person's holdings.
F4 The option is fully vested.